Gender differences in cholesterol-lowering medication prescribing in peripheral artery disease

Vascular Medicine

Volumn 16, Issue 6, 2011, Pages 428-435

  McDermott, Mary M ^a   Greenland, Philip ^a   Reed, George ^b   Mazor, Kathleen M ^b   Merriam, Philip A ^b   Graff, Rex ^a   Tao, Huimin ^a   Pagoto, Sherry ^b   Manheim, Larry ^a   Kibbe, Melina R ^a,c   Ockene, Ira S ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

intermittent claudication; peripheral artery disease; prevention; quality of care

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; DISEASE SEVERITY; EDUCATION; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF CONCEPT; TREATMENT OUTCOME;

AGED; CHOLESTEROL, LDL; COMORBIDITY; DIRECTIVE COUNSELING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTERMITTENT CLAUDICATION; LEG; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; PERIPHERAL ARTERIAL DISEASE; SEX FACTORS; TELEPHONE;

EID: 82955217706     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X11425879     Document Type: Article

References (21)

1. Heald CL, Fowkes FG, Murray GD, Price JF. Ankle brachial index collaboration. Atherosclerosis. 2006 ; 189: 61-69
2. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: A meta-analysis. JAMA. 2008 ; 300: 197-208
3. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet. 2002 ; 360: 7-22
4. Waters DD, Brotons C, Chiang CW, et al. Lipid Treatment Assessment Project 2: A multinational survey to evaluate the proportion of patients achieving low density lipoprotein cholesterol goals. Circulation. 2009 ; 120: 28-34
5. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively modified in peripheral arterial disease than in coronary artery disease. J Gen Intern Med. 1997 ; 12: 209-215 (Pubitemid 27175894)
6. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001 ; 286: 1317-1324 (Pubitemid 33015522)
7. Selvin E, Hirsch AT. Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999-2004. Atherosclerosis. 2008 ; 201: 425-433
8. McDermott MM, Reed G, Greenland P, et al. Activating peripheral arterial disease patients to achieve ideal cholesterol: A randomized controlled trial. Am J Med. 2011 ; 124: 557-565
9. McDermott MM, Mazor KM, Reed G, et al. Attitudes and behavior of peripheral arterial disease patients toward influencing their physician's prescription of cholesterol-lowering medication. Vasc Med. 2009 ; 15: 83-90
10. Grundy SM, Cleeman JI, Merz CN, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004 ; 44: 720-723
11. McDermott MM, Ades P, Guralnik JM, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: A randomized controlled clinical trial. JAMA. 2009 ; 301: 165-174
12. Ryan P Stata Technical Bulletin. College Station, TX: Stata Press ; 1998: 297-300.
13. Ryan P. Update to random allocation of treatment to blocks. Stata Technical Bulletin. 1999 ; 50: 36-37
14. Tate JR, Rifai N, Berg K, et al. International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clin Chem. 1998 ; 44 (8 Pt 1). 1629-1640 (Pubitemid 28381204)
15. Maly RC, Frank JC, Marshall GN, et al. Perceived efficacy in patient-physician interactions (PEPPI): Validation of an instrument in older persons. J Am Geriatr Soc. 1998 ; 46: 889-894 (Pubitemid 28328506)
16. Hibbard JH, Stackard J, Mahoney ER, Tusler M. Development of the patient activation measure (PAM): Conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004 ; 39: 1005-1026 (Pubitemid 38924690)
17. Arch Intern Med. Lyness JM Noel TK Cox C King DA Conwell Y Caine ED, ed. 1997: 449-454.
18. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998 ; 81: 582-587 (Pubitemid 28182422)
19. Crouse JR, Frohlich J, Ose L, et al. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 1999 ; 83: 1476-1477 (Pubitemid 29228345)
20. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003 ; 92: 152-160 (Pubitemid 36835963)
21. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997 ; 12: 209-215 (Pubitemid 27175894)